DRUG: LP-168
DRUG: LP-168
DRUG: Odronextamab
BIOLOGICAL: Peripheral Blood Stem Cell Transplant
DRUG: Allopurinol 300 MG
DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: Bone Marrow Cell Transplant
RADIATION: Total Body Irradiation
DRUG: Sirolimus Pill
DRUG: Mycophenolate Mofetil
GENETIC: ADI-001
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: ACE1831
DRUG: Obinutuzumab
PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
PROCEDURE: Computed Tomography
DRUG: Etoposide
DRUG: Ifosfamide
DRUG: Lenalidomide
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Tafasitamab
BIOLOGICAL: EO2463
DRUG: lenalidomide
BIOLOGICAL: rituximab
DRUG: CD22CART Infusion
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Cyclophosphamide
DRUG: Cyclosporine
BIOLOGICAL: Filgrastim
DRUG: Fludarabine
DRUG: Mycophenolate Mofetil
DRUG: Mycophenolate Sodium
RADIATION: Total-Body Irradiation
DRUG: Treosulfan
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Echocardiography
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Positron Emission Tomography
DRUG: Zanubrutinib
DRUG: Acalabrutinib
BIOLOGICAL: Obinutuzumab
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: NX-2127
DRUG: voruciclib monotherapy
DRUG: voruciclib and venetoclax
DRUG: Selinexor
BIOLOGICAL: CNTY-101
BIOLOGICAL: IL-2
DRUG: Lymphodepleting Chemotherapy
DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells
DRUG: Bendamustine
PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration and Biopsy
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
PROCEDURE: Echocardiography
DRUG: Fludarabine
PROCEDURE: Leukapheresis
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
DRUG: CD47 Antagonist ALX148
DRUG: Lenalidomide
BIOLOGICAL: Rituximab
DRUG: Polatuzumab vedotin
DRUG: Mosunetuzumab
DRUG: Lenalidomide
DRUG: SC291
DRUG: Iopofosine I 131 single dose
DRUG: Iopofosine I 131 multiple dose
DRUG: Iopofosine I 131 fractionated dose
DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
DRUG: Prednisone
BIOLOGICAL: Rituximab
DRUG: Vincristine Sulfate
DRUG: Zanubrutinib
DRUG: BGB-16673
BIOLOGICAL: CTX112
PROCEDURE: Biospecimen Collection
DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
DRUG: Oral Azacitidine
DRUG: Prednisone
OTHER: Questionnaire Administration
BIOLOGICAL: Rituximab
DRUG: Vincristine Sulfate
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Mosunetuzumab
PROCEDURE: Positron Emission Tomography
OTHER: Questionnaire Administration
RADIATION: Ultra Low Dose 4 Gy Radiation
DRUG: Odronextamab
DRUG: Lenalidomide
DRUG: Rituximab
DRUG: Loncastuximab tesirine 150 µg/Kg
DRUG: Loncastuximab tesirine 75µg/Kg
DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Fludarabine
DRUG: Cyclophosphamide
RADIATION: Total Body Irradiation
DRUG: Cyclosporine A
DRUG: Mycophenylate mofetil
BIOLOGICAL: Umbilical cord blood
DRUG: ABBV-101
DRUG: SGR-1505
DRUG: CD79b-19 CAR T cells
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Venetoclax
DRUG: Lenalidomide
BIOLOGICAL: Rituximab
BIOLOGICAL: Rituximab and Hyaluronidase Human
DRUG: AS-1763
DRUG: AC676
BIOLOGICAL: Mosunetuzumab
BIOLOGICAL: Obinutuzumab
DRUG: Polatuzumab Vedotin
DRUG: L-Bcl-2 antisense oligonucleotide
DRUG: SC262
DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Obinutuzumab
DRUG: Ibrutinib
BIOLOGICAL: Obinutuzumab
OTHER: Laboratory Biomarker Analysis
DRUG: PRT2527
DRUG: Zanubrutinib
DRUG: Venetoclax
DRUG: NX-5948
BIOLOGICAL: HSCT with TBI Regimen
BIOLOGICAL: HSCT with Non-TBI Regimen
BIOLOGICAL: 8/12-Day Production of Car-T Cells
BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells
BIOLOGICAL: 12-Day Production of Car-T Cells
DRUG: CAR.k.28
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Bendamustine
Get the latest thought leadership on your Marginal Zone Lymphoma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.